

Update with the development of Ebola vaccines and¹
implications to inform policy recommendations



Introduction & questions for SAGE's consideration

Fred Were, Co-chair, Ebola WG
SAGE meeting, 23–25 October 2018

WG on Ebola vaccines and vaccination

Terms of Reference

To facilitate the review, the Working Group will provide technical advice and support to the WHO secretariat by reviewing:

- **the essential evidence** required for making policy recommendations and on strategies for deployment of vaccines.
- **the available epidemiological data** to define the risk of disease and mortality in different population groups in order to allow prioritization of vaccination.
- the evidence, as it becomes available, on **the safety, and efficacy of candidate vaccines**, including the optimal vaccination schedules to be used for each vaccine.

WG on Ebola vaccines and vaccination

Terms of Reference (2)

- the data on the **projected impact of different vaccination strategies** generated by mathematical models.
- the **projections of vaccine supply** to inform recommendations on the deployment of vaccines.

Prepare the synthesis of the above data for presentation to SAGE and in drafting recommendations for consideration by SAGE.

Today's session

1	Introduction	F. Were Co-Chair of the Ebola WG
2	Overview of Ebola epidemiology	D. Heymann LSHTM, Public Health England and Chatham House
3	Update on Ebola candidate vaccines	A.M. Henao-Restrepo Initiative for Vaccine Research, WHO
4	Benefits and risk analysis of vaccination of pregnant women with rVSV-ZEBOV as part of Expanded Access/Compassionate Use during Ebola outbreaks.	C. Jarvis and J. Edmunds LSHTM
4	Observed and forecasted impact of different candidate Ebola vaccines immunization strategies and target populations	A. Camacho Epicentre
6	Conclusions and proposed recommendations	F. Were Co-Chair of the Ebola WG
7	Discussion	

Evidence reviewed

1. EVD epidemiology
2. Characteristics of candidate Ebola vaccines in clinical development
3. Private reports by each vaccine developer (closed session SAGE WG Members only)
4. Modelled impact of different vaccine delivery strategies
5. rVSVΔG-ZEBOV-GP use under Expand Access framework during outbreaks
6. Strategies to ensure Pre-licensure and Post-licensure access
7. WHO Target Product Profiles and current regulatory pathways
8. Current and planned efforts to further support epidemic vaccine R&D
9. Preliminary conclusions and deliberation on proposed questions for SAGE (closed session SAGE WG Members only)

Questions for SAGE

1. Are there **remaining challenges that may prevent access to Ebola vaccines** in future outbreaks? If yes, can SAGE make recommendations on how these might be addressed?
2. Is the current **evidence sufficient for SAGE to adjust current recommendations** regarding the use of Ebola vaccines in case of another Ebola outbreak?
 - If yes, which recommendations can be proposed?
 - What key data are missing?
3. What are the **conclusions from the benefits and risk analysis of vaccination of pregnant women** with rVSV-ZEBOV as part of Expanded Access/ Compassionate Use during Ebola outbreaks?



Thank you